<code id='05B9DFCFC7'></code><style id='05B9DFCFC7'></style>
    • <acronym id='05B9DFCFC7'></acronym>
      <center id='05B9DFCFC7'><center id='05B9DFCFC7'><tfoot id='05B9DFCFC7'></tfoot></center><abbr id='05B9DFCFC7'><dir id='05B9DFCFC7'><tfoot id='05B9DFCFC7'></tfoot><noframes id='05B9DFCFC7'>

    • <optgroup id='05B9DFCFC7'><strike id='05B9DFCFC7'><sup id='05B9DFCFC7'></sup></strike><code id='05B9DFCFC7'></code></optgroup>
        1. <b id='05B9DFCFC7'><label id='05B9DFCFC7'><select id='05B9DFCFC7'><dt id='05B9DFCFC7'><span id='05B9DFCFC7'></span></dt></select></label></b><u id='05B9DFCFC7'></u>
          <i id='05B9DFCFC7'><strike id='05B9DFCFC7'><tt id='05B9DFCFC7'><pre id='05B9DFCFC7'></pre></tt></strike></i>

          knowledge

          knowledge

          author:fashion    Page View:5366
          Adobe

          Venture firms backing health tech startups are telegraphing cautious optimism for 2024, advising startups to expect smaller and fewer checks as well as possible market consolidation but not to abandon hope just yet as investments stabilize following a sharp drop-off.

          As customers — often health systems, payers, or employers — and backers plot how they’ll invest shrinking budgets, they’re increasingly savvy about metrics, investors told STAT. They’re also less interested in rapid growth, and more keen on startups that can demonstrate savings and efficiency.

          advertisement

          That’s a sharp contrast from the unrestrained health tech investments that peaked in 2021, fueled by a pandemic-era frenzy for virtual appointments, mental health care and app-based therapies.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more
          H.R. 3 is the wrong path to lower drug costs
          H.R. 3 is the wrong path to lower drug costs

          Fromleft,Rep.RichardNeal(D-Mass.)speaksasRep.FrankPallone(D-N.J.)andHouseSpeakerNancyPelosi(D-Calif.

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          Readout LOUD podcast: possible new ALS drug, artificial wombs

          CantheFDAbetooflexible?Howdoyoutestamechanicalwomb?Andwhodecideswhat’sgoodenoughforpatientsinneed?We